AriAdPharmaceuticals.org
Title
Signaling Pathways to Better Health - ARIAD
Description
Excerpted from the website description:
- ARIAD is developing breakthrough medicines that regulate cell-signaling pathways implicated in cancer. Our pipeline includes a series of small molecule product candidates that provide targeted and highly potent anti-cancer activity to treat solid tumors and hematologic cancers, as well as the spread of tumors to distant sites. Our lead candidate — deforolimus, a novel mTOR inhibitor—has been given fast track designation by the FDA for the treatment of soft-tissue and bone sarcomas.
Languages
English
Additional Information
Related Domains
External Links
Domain Resolution
This domain resolves to the following IP addresses:
Categories:
- 70
- AP1903
- ARGENT
- Anemia
- BMT
- Bone Marrow Transplantation
- Bone Resorption
- Cancer Drug
- Conditional Knock-out
- Dimerizer
- Dimerizer Drug
- Drug Screening
- Epo
- Erythropoietin
- Functional Genomics
- Gene
- Gene Activation
- Gene Regulation
- Gene Switch
- Gene Therapy
- Graft-vs-host Disease
- Graft-vs-host Disease Cell Therapy
- GvHD
- Heterodimerization
- Homodimerization
- Immune Diseases
- Inducible Gene Expression
- Inducible Knock-out Mouse
- Inflammation
- Kinase Inhibitor
- Mouse
- NF-AT
- NF-kB
- NF-kappaB
- NFkB
- Orally Active Protein Therapy
- Osteoporosis Drug
- Product Validation
- Protein Engineering
- Proteomics
- RGE
- RPD
- Rage
- Rapamycin
- Rapid
- Regulated Cell Therapy
- Regulated Gene Therapy
- Regulated Gene Transcription
- Regulated Protein Secretion
- Regulated Signal Transduction
- Regulation Kit
- Signal Transduction
- Signal Transduction Inhibitors
- Small Molecule
- Src
- Stem Cell Therapy
- Structure-based Drug Design
- Target Validation
- Tyrosine Kinase
- ZAP